Document:

Exhibit 4.2

 

THIS WARRANT AND THE SECURITIES ISSUABLE
UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
OR ANY OTHER SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF (1)
AN EFFECTIVE REGISTRATION STATEMENT COVERING SUCH SECURITIES UNDER THE SECURITIES ACT AND ANY OTHER APPLICABLE SECURITIES LAWS,
OR (2) AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

IN ADDITION, THIS WARRANT AND THE SECURITIES
ISSUABLE UPON EXERCISE HEREOF MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED, OR BE THE SUBJECT OF ANY HEDGING,
SHORT SALE, DERIVATIVE, PUT, OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF SUCH SECURITIES BY
ANY PERSON FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS IMMEDIATELY FOLLOWING THE DATE OF EFFECTIVENESS OF THE PUBLIC OFFERING
OF THE COMPANY’S SECURITIES PURSUANT TO REGISTRATION STATEMENT NO.: 333-208694 AS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION, EXCEPT IN ACCORDANCE WITH FINRA RULE 5110(G)(2).

 

CUE BIOPHARMA, INC.

 

UNDERWRITER WARRANT

 

Warrant No. U2017-1

 

[●] shares of Common Stock

 

[_______], 2017

 

This UNDERWRITER
WARRANT (this “Warrant”) of Cue Biopharma, Inc., a corporation duly organized and validly existing under
the laws of the State of Delaware (the “Company”), is being issued pursuant to that certain Underwriting
Agreement, dated [_______], 2017 (the “Underwriting Agreement”), between the Company and MDB Capital
Group, LLC as representative of the underwriters (the “Underwriters”) relating to a best efforts public offering
(the “Offering”) of shares of common stock, $0.001 par value, of the Company (the “Common Stock”).

 

FOR VALUE RECEIVED, the
Company hereby grants to [__________] and its permitted successors and assigns (collectively, the “Holder”)
the right to purchase from the Company up to [●] shares of Common Stock (such shares underlying this Warrant, the “Warrant
Shares”), at a per share purchase price equal to $[125% of the Public Offering Price] (the “Exercise
Price”), subject to the terms, conditions and adjustments set forth below in this Warrant.

 

     

     

    

 

1.           Date
of Warrant Exercise. This Warrant shall become exercisable one hundred eighty (180) days after the Base Date (the “Exercise
Date”). As used in this Warrant, the term “Base Date” shall mean [_______], 2017 (the effective date
of the registration statement). Except as otherwise provided for herein or as permitted by applicable rules of the Financial Industry
Regulatory Authority, Inc. (“FINRA”), this Warrant and the underlying Warrant Shares shall not be sold, transferred,
assigned, pledged or hypothecated prior to the date that is one hundred eighty (180) days immediately following the Base Date pursuant
to FINRA Rule 5110(g)(1), except as permitted under FINRA Rule 5110(g)(2).

 

2.           Expiration
of Warrant. This Warrant shall expire on the five (5) year anniversary of the Base Date (the “Expiration Date”).

 

3.           Exercise
of Warrant. This Warrant shall be exercisable pursuant to the terms of this Section 3.

 

3.1         Manner
of Exercise.

 

(a)          This
Warrant may only be exercised by the Holder hereof on or after the Exercise Date and on or prior to the Expiration Date, in accordance
with the terms and conditions hereof, in whole or in part (but not as to fractional shares) with respect to any portion of this
Warrant, during the Company’s normal business hours on any day other than a Saturday or a Sunday or a day on which commercial
banking institutions in New York, New York are authorized by law to be closed (a “Business Day”), by surrender
of this Warrant to the Company at its office maintained pursuant to Section 10.2(a) hereof, accompanied by a written exercise
notice in the form attached as Exhibit A to this Warrant (or a reasonable facsimile thereof) duly executed by the Holder,
together with the payment of the aggregate Exercise Price for the number of Warrant Shares purchased upon exercise of this Warrant.
Upon surrender of this Warrant, the Company shall cancel this Warrant document and shall, in the event of partial exercise, replace
it with a new Warrant document in accordance with Section 3.3. The Exercise Price may be paid in a “cashless”
or “cash” exercise or a combination thereof pursuant to Section 3.1(b) and Section 3.1(c) below; provided,
however, that, if at any time during the term of this Warrant there is no effective registration statement registering the
Warrant Shares under the Securities Act, or no current prospectus available for, the issuance or resale of the Warrant Shares by
the Holder, then this Warrant may only be exercised at such time by means of a “cashless” exercise.

 

(b)          Except
as provided for in Section 3.1(c) below, each exercise of this Warrant must be accompanied by payment in full of the aggregate
Exercise Price in cash by check or wire transfer in immediately available funds for the number of Warrant Shares being purchased
by the Holder upon such exercise.

 

    	 	2	 

     

    

 

(c)          Subject
to Section 3.1(a) and the other terms and conditions of this Warrant, the aggregate Exercise Price for the number of Warrant
Shares being purchased may also be paid in full or in part on a “cashless” basis:

 

		(i)	in the form of Common Stock owned by the Holder (based on the Fair Market Value (as defined below)
of such Common Stock on the date of exercise);

 

		(ii)	in the form of Warrant Shares withheld by the Company from the Warrant Shares otherwise to be received
upon exercise of this Warrant having an aggregate Fair Market Value on the date of exercise equal to the aggregate Exercise Price
of the Warrant Shares being purchased by the Holder; or

 

		(iii)	by a combination of the foregoing, provided that the combined value of all cash and the Fair Market
Value of any shares surrendered to the Company is at least equal to the aggregate Exercise Price for the number of Warrant Shares
being purchased by the Holder.

 

For purposes of this
Warrant, the term “Fair Market Value” shall be the closing price on the trading day immediately preceding the
applicable exercise herein as officially reported by the principal securities exchange on which the Common Stock is then listed
or admitted to trading, or, if the Common Stock is not listed or admitted to trading on any securities exchange as determined in
good faith by resolution of the Board of Directors of the Company, based on the best information available to it.

 

To illustrate a cashless
exercise of this Warrant under Section 3.1(c)(ii) (or for a portion thereof for which cashless exercise treatment is requested
as contemplated by Section 3.1(c)(iii) hereof), the calculation of such exercise shall be as follows:

 

X = Y (A-B)/A

 

where:

 

	 	X =	the number of Warrant Shares to be issued to the Holder (rounded to the nearest whole share).

 

	 	Y =	the number of Warrant Shares with respect to which this Warrant is being exercised.

 

	 	A =	the Fair Market Value of the Common Stock.

 

	 	B =	the Exercise Price.

 

    	 	3	 

     

    

 

(d)          For
purposes of Rule 144 and sub-section (d)(3)(ii) thereof, it is intended, understood, and acknowledged that the Common Stock issuable
upon exercise of this Warrant in a cashless exercise transaction as described in Section 3.1(c) above shall be deemed to
have been acquired at the time this Warrant was issued. Moreover, it is intended, understood, and acknowledged that the holding
period for the Common Stock issuable upon exercise of this Warrant in a cashless exercise transaction as described in Section
3.1(c) above shall be deemed to have commenced on the date this Warrant was issued.

 

3.2         When
Exercise Effective. Each exercise of this Warrant shall be deemed to have been effected immediately prior to the close of business
on the Business Day on which this Warrant shall have been duly exercised as provided in Sections 3.1 and 12 hereof, and,
at such time, the Holder in whose name any certificate or certificates for Warrant Shares shall be issuable upon exercise as provided
in Section 3.3 hereof shall be deemed to have become the holder or holders of record thereof of the number of Warrant Shares
purchased upon exercise of this Warrant.

 

3.3         Delivery
of Common Stock Certificates and New Warrant. As soon as reasonably practicable after each exercise of this Warrant, in whole
or in part, and in any event within three (3) Business Days thereafter, the Company, at its expense (including the payment by it
of any applicable issue taxes), will cause to be issued in the name of and delivered to the Holder hereof or, subject to Sections
9 and 10 hereof, as the Holder (upon payment by the Holder of any applicable transfer taxes) may direct:

 

(a)          a
certificate or certificates (with appropriate restrictive legends, as applicable) for the number of duly authorized, validly issued,
fully paid and non-assessable Warrant Shares to which the Holder shall be entitled upon exercise; and

 

(b)          in
case exercise is in part only, a new Warrant document of like tenor, dated the date hereof, for the remaining number of Warrant
Shares issuable upon exercise of this Warrant after giving effect to the partial exercise of this Warrant (including the delivery
of any Warrant Shares as payment of the Exercise Price for such partial exercise of this Warrant).

 

    	 	4	 

     

    

 

4.           Certain
Adjustments. For so long as this Warrant is outstanding:

 

4.1         Mergers
or Consolidations. If at any time after the date hereof there shall be a capital reorganization (other than a combination or
subdivision of Common Stock otherwise provided for herein) resulting in a reclassification to or change in the terms of securities
issuable upon exercise of this Warrant (a “Reorganization”), or a merger or consolidation of the Company with
another corporation, association, partnership, organization, business, individual, government or political subdivision thereof
or a governmental agency (a “Person” or the “Persons”) (other than a merger with another
Person in which the Company is a continuing corporation and which does not result in any reclassification or change in the terms
of securities issuable upon exercise of this Warrant or a merger effected exclusively for the purpose of changing the domicile
of the Company) (a “Merger”), then, as a part of such Reorganization or Merger, lawful provision and adjustment
shall be made so that the Holder shall thereafter be entitled to receive, upon exercise of this Warrant, the number of shares of
stock, equity or debt securities, cash or other property receivable upon such Reorganization or Merger by a holder of the number
of shares of Common Stock which might have been purchased upon exercise of this Warrant immediately prior to such Reorganization
or Merger. In any such case, appropriate adjustment shall be made in the application of the provisions of this Warrant with respect
to the rights and interests of the Holder after the Reorganization or Merger to the end that the provisions of this Warrant (including
adjustment of the Exercise Price then in effect and the number of Warrant Shares) shall be applicable after that event, as near
as reasonably may be, in relation to any shares of stock, equity or debt securities, cash or other property thereafter deliverable
upon exercise of this Warrant. The provisions of this Section 4.1 shall similarly apply to successive Reorganizations and/or
Mergers.

 

4.2         Splits
and Subdivisions; Dividends. In the event the Company should at any time or from time to time effectuate a split or subdivision
of the outstanding shares of Common Stock or pay a dividend in or make a distribution payable in additional shares of Common Stock
or other securities, or rights convertible into, or entitling the holder thereof to receive, directly or indirectly, additional
shares of Common Stock (hereinafter referred to as “Common Stock Equivalents”) without payment of any consideration
by such holder for the additional shares of Common Stock or Common Stock Equivalents (including the additional shares of Common
Stock issuable upon conversion or exercise thereof), then, as of the applicable record date (or the date of such distribution,
split or subdivision if no record date is fixed), the per share Exercise Price shall be appropriately decreased and the number
of Warrant Shares shall be appropriately increased in proportion to such increase (or potential increase) of outstanding shares;
provided, however, that no adjustment shall be made in the event the split, subdivision, dividend or distribution
is not effectuated. Notwithstanding the foregoing or anything else to the contrary herein, in no event shall the per share Exercise
Price be reduced below the par value of one Common Share or of such other securities as may be issued upon exercise of the Warrant.

 

Pursuant to the adjustment
terms of this Section 4.2, provided that the shareholders are proportionally affected by such split or subdivision, dividend,
distribution, or other similar event, the Holder may receive a greater number of Warrant Shares or the per share Exercise Price
may be lower than originally contemplated by this Warrant. Additionally, the Holder shall not have the right to accrue cash dividends
prior to the exercise or conversion of the Warrant.

 

    	 	5	 

     

    

 

4.3         Combination
of Shares. If the number of shares of Common Stock outstanding at any time after the date hereof is decreased by a combination
of the outstanding shares of Common Stock, the per share Exercise Price shall be appropriately increased and the number of shares
of Warrant Shares shall be appropriately decreased in proportion to such decrease in outstanding shares.

 

4.4         Adjustments
for Other Distributions. In the event the Company shall declare a distribution payable in securities of other Persons, evidences
of indebtedness issued by the Company or other Persons, assets (excluding cash dividends or distributions to the holders of Common
Stock paid out of current or retained earnings and declared by the Company’s Board of Directors) or options or rights not
referred to in Sections 4.2 or 4.3 then, in each such case for the purpose of this Section 4.4, upon exercise
of this Warrant, the Holder shall be entitled to a proportionate share of any such distribution as though the Holder was the actual
record holder of the number of Warrant Shares as of the record date fixed for the determination of the holders of Common Stock
of the Company entitled to receive such distribution.

 

5.           No
Impairment. The Company will not, by amendment of its certificate of incorporation or by-laws or through any consolidation,
merger, reorganization, transfer of assets, dissolution, issue or sale of securities or any other voluntary action, avoid or seek
to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying
out of all of the terms and in the taking of all actions necessary or appropriate in order to protect the rights of the Holder
against impairment.

 

6.           Notice
as to Adjustments. With respect to each adjustment pursuant to Section 4 of this Warrant, the Company, at its expense,
will promptly compute the adjustment or re-adjustment in accordance with the terms of this Warrant and furnish the Holder with
a certificate certified and confirmed by the Secretary or Chief Financial Officer of the Company setting forth, in reasonable detail,
the event requiring the adjustment or re-adjustment and the amount of such adjustment or re-adjustment, the method of calculation
thereof and the facts upon which the adjustment or re-adjustment is based, and the Exercise Price and the number of Warrant Shares
or other securities purchasable hereunder after giving effect to such adjustment or re-adjustment, which report shall be mailed
by first class mail, postage prepaid to the Holder.

 

    	 	6	 

     

    

 

7.           Reservation
of Shares. The Company shall, solely for the purpose of effecting the exercise of this Warrant, at all times during the term
of this Warrant, reserve and keep available out of its authorized shares of Common Stock, free from all taxes, liens and charges
with respect to the issue thereof and not subject to preemptive rights of shareholders of the Company, such number of its shares
of Common Stock as shall from time to time be sufficient to effect in full the exercise of this Warrant. If at any time the number
of authorized but unissued shares of Common Stock shall not be sufficient to effect in full the exercise of this Warrant, in addition
to such other remedies as shall be available to Holder, the Company will promptly take such corporate action as may, in the opinion
of its counsel, be necessary to increase the number of authorized but unissued shares of Common Stock to such number of shares
as shall be sufficient for such purposes, including without limitation, using its Reasonable Commercial Efforts (as defined in
Section 14 hereof) to obtain the requisite shareholder approval necessary to increase the number of authorized shares of
Common Stock. The Company hereby represents and warrants that all shares of Common Stock issuable upon proper exercise of this
Warrant shall be duly authorized and, when issued and paid for upon proper exercise, shall be validly issued, fully paid and nonassessable.

 

8.           Registration
and Listing.

 

8.1         Definition
of Registrable Securities; Majority. As used herein, the term “Registrable Securities” means any shares
of Common Stock issuable upon the exercise of this Warrant until the date (if any) on which such shares shall have been transferred
or exchanged and new certificates for them not bearing a legend restricting further transfer shall have been delivered by the Company
and subsequent disposition of the shares shall not require registration or qualification under the Securities Act or any similar
state law then in force. For purposes of this Warrant, the term “Majority Holders” shall mean holders of in
excess of fifty percent (50%) of the then outstanding Warrant Shares covered by original Warrant No. U2017-1 (assuming the exercise
of the entire Warrant).

 

8.2         Demand
Registration Rights.

 

(a)          If
at any time after the date hereof and on or before the Expiration Date there is no effective registration statement registering
the Warrant Shares under the Securities Act, or no current prospectus available for, the issuance or resale of the Warrant Shares
by the Holder, the Company, upon written demand (“Demand Notice”) of the Majority Holders, agrees to register
on one occasion all of the Registrable Securities (a “Demand Right”). On such occasion, the Company will file
a registration statement or a post-effective amendment to the Registration Statement covering the Registrable Securities within
forty-five (45) days after receipt of a Demand Notice and use its Reasonable Commercial Efforts to have such registration statement
or post-effective amendment declared effective as soon as possible thereafter. The Company covenants and agrees to give written
notice of its receipt of any Demand Notice by any Holder(s) to all other registered Holders of the Warrants and/or the Registrable
Securities within ten (10) days from the date of the receipt of any such Demand Notice.

 

    	 	7	 

     

    

 

(b)          Registration
of Registrable Securities under this Section 8.2 shall be on such appropriate registration form: (i) as shall be selected
by the Company; and (ii) as shall permit the disposition of such Registrable Securities in accordance with this Section 8.2.
The Company agrees to include in any such registration statement all information which the requesting holders of Registrable Securities
shall reasonably request, which is required to be contained therein. The Company shall bear all fees and expenses attendant to
registering the Registrable Securities pursuant to Section 8.2, but the Holders shall pay any and all underwriting commissions
and the expenses of any legal counsel selected by the Holders to represent them in connection with the sale of the Registrable
Securities. The Company agrees to use its Reasonable Commercial Efforts to qualify or register the Registrable Securities in such
states as are reasonably requested by the Majority Holder(s); provided, however, that in no event shall the Company
be required to register the Registrable Securities in a state in which such registration would cause (i) the Company to be obligated
to register, license or qualify to do business in such state, submit to general service of process in such state or would subject
the Company to taxation as a foreign corporation doing business in such jurisdiction, or (ii) the principal stockholders of the
Company to be obligated to escrow their shares of capital stock of the Company. The Company shall cause any registration statement
or post-effective amendment filed pursuant to the demand right granted under Section 8.2(a) to remain effective for a period
of nine consecutive months from the effective date of such registration statement or post-effective amendment. The Holders shall
only use the prospectuses provided by the Company to sell the Registrable Securities covered by such registration statement, and
will immediately cease to use any prospectus furnished by the Company if the Company advises the Holder that such prospectus may
no longer be used due to a material misstatement or omission.

 

8.3         Incidental
Registration Rights.

 

(a)          If
the Company, for a period of seven (7) years commencing from the Base Date, proposes to register any of its securities under the
Securities Act (other than in connection with a transaction contemplated by Rule 145(a) promulgated under the Securities Act, pursuant
to registration on Form S-4 or S-8 or any successor forms) whether for its own account or for the account of any holder or holders
of its shares other than Registrable Securities (any shares of such holder or holders (but not those of the Company and not Registrable
Securities) with respect to any registration are referred to herein as, “Other Shares”), the Company shall at
each such time give prompt (but not less than thirty (30) days prior to the anticipated effectiveness thereof) written notice to
the holders of Registrable Securities of its intention to do so. The holders of Registrable Securities shall exercise the “piggy-back”
rights provided herein by giving written notice within ten (10) days after the receipt of any such notice (which request shall
specify the Registrable Securities intended to be disposed of by such holder). Except as set forth in Section 8.3(b), the
Company will use its Reasonable Commercial Efforts to effect the registration under the Securities Act of all of the Registrable
Securities which the Company has been so requested to register by such holder, to the extent required to permit the disposition
of the Registrable Securities so to be registered, by inclusion of such Registrable Securities in the registration statement which
covers the securities which the Company proposes to register. The Company will pay all Registration Expenses in connection with
each registration of Registrable Securities pursuant to this Section 8.3.

 

    	 	8	 

     

    

 

(b)          If
the Company at any time proposes to register any of its securities under the Securities Act as contemplated by this Section
8.3 and such securities are to be distributed by or through one or more underwriters, the Company will, if requested by a holder
of Registrable Securities, use its Reasonable Commercial Efforts to arrange for such underwriters to include all the Registrable
Securities to be offered and sold by such holder among the securities to be distributed by such underwriters, provided that if
the managing underwriter of such underwritten offering shall inform the Company by letter of its belief that inclusion in such
distribution of all or a specified number of such securities proposed to be distributed by such underwriters would interfere with
the successful marketing of the securities being distributed by such underwriters (such letter to state the basis of such belief
and the approximate number of such Registrable Securities, such Other Shares and shares held by the Company proposed so to be registered
which may be distributed without such effect), then the Company may, upon written notice to such holder, the other holders of Registrable
Securities, and holders of such Other Shares, reduce pro rata in accordance with the number of shares of Common Stock desired to
be included in such registration (if and to the extent stated by such managing underwriter to be necessary to eliminate such effect)
the number of such Registrable Securities and Other Shares the registration of which shall have been requested by each holder thereof
so that the resulting aggregate number of such Registrable Securities and Other Shares so included in such registration, together
with the number of securities to be included in such registration for the account of the Company, shall be equal to the number
of shares stated in such managing underwriter’s letter.

 

8.4         Registration
Procedures. Whenever the holders of Registrable Securities have properly requested that any Registrable Securities be registered
pursuant to the terms of this Warrant, the Company shall use its Reasonable Commercial Efforts to effect the registration for the
sale of such Registrable Securities in accordance with the intended method of disposition thereof, and pursuant thereto the Company
shall as expeditiously as possible:

 

(a)          prepare
and file with the Securities and Exchange Commission (“SEC”) a registration statement with respect to such Registrable
Securities and use its Reasonable Commercial Efforts to cause such registration statement to become effective;

 

(b)          notify
such holders of the effectiveness of each registration statement filed hereunder and prepare and file with the SEC such amendments
and supplements to such registration statement and the prospectus used in connection therewith as may be necessary to (i) keep
such registration statement effective and the prospectus included therein usable for a period commencing on the date that such
registration statement is initially declared effective by the SEC and ending on the date when all Registrable Securities covered
by such registration statement have been sold pursuant to the registration statement or cease to be Registrable Securities, and
(ii) comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration
statement during such period in accordance with the intended methods of disposition by the sellers thereof set forth in such registration
statement;

 

    	 	9	 

     

    

 

(c)          furnish
to such holders such number of copies of such registration statement, each amendment and supplement thereto, the prospectus included
in such registration statement (including each preliminary prospectus) and such other documents as such seller may reasonably request
in order to facilitate the disposition of the Registrable Securities owned by such holders;

 

(d)          use
its Reasonable Commercial Efforts to register or qualify such Registrable Securities under such other securities or blue sky laws
of such jurisdictions as such holders reasonably request and do any and all other acts and things which may be reasonably necessary
or advisable to enable such holders to consummate the disposition in such jurisdictions of the Registrable Securities owned by
such holders, including, without limitation, any applicable FINRA filings within the time mandated by applicable FINRA rules, including
without limitations Rule 5110(b); provided, however, that the Company shall not be required to: (i) qualify generally to do business
in any jurisdiction where it would not otherwise be required to qualify but for this subparagraph; (ii) subject itself to taxation
in any such jurisdiction; or (iii) consent to general service of process in any such jurisdiction;

 

(e)          notify
such holders, at any time when a prospectus relating thereto is required to be delivered under the Securities Act, of the happening
of any event as a result of which the prospectus included in such registration statement contains an untrue statement of a material
fact or omits any material fact necessary to make the statements therein, in light of the circumstances in which they are made,
not materially misleading, and, at the reasonable request of such holders, the Company shall prepare a supplement or amendment
to such prospectus so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall not
contain an untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in
light of the circumstances in which they are made, not materially misleading;

 

(f)          provide
a transfer agent and registrar for all such Registrable Securities not later than the effective date of such registration statement;

 

(g)         make
available for inspection by any underwriter participating in any disposition pursuant to such registration statement, and any attorney,
accountant or other agent retained by any such underwriter, all financial and other records, pertinent corporate documents and
properties of the Company, and cause the Company’s officers, directors, managers, employees and independent accountants to
supply all information reasonably requested by any such underwriter, attorney, accountant or agent in connection with such registration
statement;

 

    	 	10	 

     

    

 

(h)         otherwise
use its Reasonable Commercial Efforts to comply with all applicable rules and regulations of the SEC, and make available to such
holders, as soon as reasonably practicable, an earnings statement of the Company, which earnings statement shall satisfy the provisions
of Section 11(a) of the Securities Act and, at the option of the Company, Rule 158 thereunder;

 

(i)          in
the event of the issuance of any stop order suspending the effectiveness of a registration statement, or of any order suspending
or preventing the use of any related prospectus or suspending the qualification of any Registrable Securities included in such
registration statement for sale in any jurisdiction, the Company shall use its Reasonable Commercial Efforts promptly to obtain
the withdrawal of such order; and

 

(j)          if
the offering is underwritten, use its Reasonable Commercial Efforts to furnish on the date that Registrable Securities are delivered
to the underwriters for sale pursuant to such registration, an opinion dated such date of counsel representing the Company for
the purposes of such registration, addressed to the underwriters covering such issues as are customarily addressed in opinions
to underwriters in public offerings and reasonably required by such underwriters.

 

8.5         Expenses.
The Company shall pay all Registration Expenses relating to the registration and listing obligations set forth in this Section
8. For purposes of this Warrant, the term “Registration Expenses” means: (a) all registration, filing and
FINRA fees; (b) all reasonable fees and expenses of complying with securities or blue sky laws; (c) all word processing, duplicating
and printing expenses; (d) the fees and disbursements of counsel for the Company and of its independent public accountants, including
the expenses of any special audits or “cold comfort” letters required by or incident to such performance and compliance;
(e) premiums and other costs of policies of insurance (if any) against liabilities arising out of the public offering of the Registrable
Securities being registered if the Company desires such insurance, if any; and (f) fees and disbursements of one counsel for the
selling holders of Registrable Securities. Further, the Company shall pay its internal expenses (including, without limitation,
all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual or quarterly
review, the expense of any liability insurance and the expenses and fees for listing the Registrable Securities on each security
exchange on which the Common Stock is then listed. Registration Expenses shall not include any underwriting discounts and commissions
which may be incurred in the sale of any Registrable Securities and transfer taxes of the selling holders of Registrable Securities.

 

8.6         Listing.
The Company shall secure the listing of the Common Stock underlying this Warrant upon each national securities exchange or automated
quotation system upon which shares of Common Stock are then listed or quoted (subject to official notice of issuance) and shall
maintain such listing of shares of Common Stock. For so long as any of the Company’s Common Stock is listed on The NASDAQ
Stock Market (or such other national securities exchange or market, as applicable), the Company shall comply in all material respects
with the Company’s reporting, filing and other obligations under the by-laws or rules of The NASDAQ Stock Market (or such
other national securities exchange or market.

 

    	 	11	 

     

    

 

8.7         Information
Provided by Holders. Any holder of Registrable Securities included in any registration shall furnish to the Company such information
as the Company may reasonably request in writing, including, but not limited to, a completed and executed questionnaire requesting
information customarily sought of selling security holders, to enable the Company to comply with the provisions hereof in connection
with any registration referred to in this Warrant. In the event that a holder of Registrable Securities fails to provide such information
on a timely basis, and in any event within seven (7) Business Days of the Company’s written request, then the Company shall
be entitled to exclude the Registrable Securities of such holder from such registration and the Company shall nevertheless be deemed
to have satisfied its obligations hereunder with respect to such registration.

 

8.8         Effectiveness
Period. The Company shall use its Reasonable Commercial Efforts to keep each registration statement contemplated hereunder
continuously effective under the Securities Act until the date which is the earlier date of when (i) all Registrable Securities
covered by such Registration Statement have been sold, or (ii) all Registrable Securities covered by such Registration Statement
may be sold immediately without registration under the Securities Act and without volume restrictions pursuant to Rule 144 under
the Securities Act, as determined by the counsel to the Company pursuant to a written opinion letter to such effect, addressed
and reasonably acceptable to the Company’s transfer agent and the affected holders of Registrable Securities.

 

8.9         Net
Cash Settlement. Notwithstanding anything herein to the contrary, in no event will the Holder hereof be entitled to receive
a net-cash settlement as liquidated damages in lieu of physical settlement in shares of Common Stock, regardless of whether the
Common Stock underlying this Warrant is registered pursuant to an effective registration statement; provided, however,
that the foregoing will not preclude the Holder from seeking other remedies at law or equity for breaches by the Company of its
registration obligations hereunder.

 

8.10       Termination
of Registration Rights. The registration rights afforded to the Holder under this Section 8 shall terminate on the earliest
date when all Registrable Securities of the Holder either: (i) have been publicly sold by the Holder pursuant to a Registration
Statement, (ii) have been covered by an effective Registration Statement on Form S-1 or Form S-3 (or successor form), which may
be kept effective as an evergreen Registration Statement, or (iii) may be sold by the Holder within a 90 day period without registration
pursuant to Rule 144 or consistent with applicable SEC interpretive guidance (including CD&I no. 201.04 (April 2, 2007) or
similar interpretive guidance).

 

    	 	12	 

     

    

 

9.           Restrictions
on Transfer.

 

9.1         Restrictive
Legends. This Warrant and each Warrant issued upon transfer or in substitution for this Warrant pursuant to Section 10 hereof,
each certificate for Common Stock issued upon the exercise of the Warrant and each certificate issued upon the transfer of any
such Common Stock shall be transferable only upon satisfaction of the conditions specified in this Section 9. Each of the
foregoing securities shall be stamped or otherwise imprinted with a legend reflecting the restrictions on transfer set forth herein
and any restrictions required under the Securities Act or other applicable securities laws.

 

9.2         Notice
of Proposed Transfer. Prior to any transfer of any securities which are not registered under an effective registration statement
under the Securities Act (“Restricted Securities”), which transfer may only occur if there is an exemption from
the registration provisions of the Securities Act and all other applicable securities laws, the Holder shall complete the form
attached as Exhibit B to this Warrant and give written notice to the Company of the Holder’s intention to effect a
transfer (and shall describe the manner and circumstances of the proposed transfer). The following provisions shall apply to any
proposed transfer of Restricted Securities:

 

(a)          If
in the opinion of counsel for the Holder reasonably satisfactory to the Company the proposed transfer may be effected without registration
of the Restricted Securities under the Securities Act (which opinion shall state in detail the basis of the legal conclusions reached
therein), the Holder shall, upon delivery of an executed original of such opinion, thereupon be entitled to transfer the Restricted
Securities in accordance with the terms of the notice delivered by the Holder to the Company. Each certificate representing the
Restricted Securities issued upon or in connection with any transfer shall bear the restrictive legends required by Section
9.1 hereof.

 

(b)          If
the opinion called for in (i) above is not delivered, the Holder shall not be entitled to transfer the Restricted Securities until
either: (x) receipt by the Company of a further notice from such Holder pursuant to the foregoing provisions of this Section
9.2 and fulfillment of the provisions of clause (i) above; or (y) such Restricted Securities have been effectively registered
under the Securities Act.

 

9.3         Certain
Other Transfer Restrictions. Notwithstanding any other provision of this Warrant: (i) prior to the Exercise Date, this Warrant
or the Restricted Securities thereunder may only be transferred or assigned to the persons permitted under FINRA Rule 5110(g);
and (ii) subject at all times to FINRA Rule 5110(g), no opinion of counsel shall be necessary for a transfer of Restricted Securities
by the holder thereof to any Person employed by or owning equity in the Holder, if the transferee agrees in writing to be subject
to the terms hereof to the same extent as if the transferee were the original purchaser hereof and such transfer is permitted under
applicable securities laws.

 

    	 	13	 

     

    

 

9.4         Termination
of Restrictions. Except as set forth in Section 9.3 hereof and subject at all times to FINRA Rule 5110(g), the restrictions
imposed by this Section 9 upon the transferability of Restricted Securities shall cease and terminate as to any particular
Restricted Securities: (a) which shall have been effectively registered under the Securities Act; or (b) when, in the opinion of
counsel for the Company, such restrictions are no longer required in order to insure compliance with the Securities Act or Section
10 hereof. Whenever such restrictions shall cease and terminate as to any Restricted Securities, the Holder thereof shall be
entitled to receive from the Company, without expense (other than applicable transfer taxes, if any), new securities of like tenor
not bearing the applicable legends required by Section 9.1 hereof.

 

10.         Ownership,
Transfer, Sale and Substitution of Warrant.

 

10.1       Ownership
of Warrant. The Company may treat any Person in whose name this Warrant is registered in the Warrant Register maintained pursuant
to Section 10.2(b) hereof as the owner and holder thereof for all purposes, notwithstanding any notice to the contrary,
except that, if and when any Warrant is properly assigned in blank, the Company may (but shall not be obligated to) treat the bearer
thereof as the owner of such Warrant for all purposes, notwithstanding any notice to the contrary. Subject to Sections 9
and 10 hereof, this Warrant, if properly assigned, may be exercised by a new holder without a new Warrant first having been
issued.

 

10.2       Office;
Exchange of Warrant.

 

(a)          The
Company will maintain its principal office at the location identified in the prospectus relating to the Offering or at such other
offices as set forth in the Company’s most current filing (as of the date notice is to be given) under the Securities Exchange
Act of 1934, as amended, or as the Company otherwise notifies the Holder.

 

(b)          The
Company shall cause to be kept at its principal office a Warrant Register for the registration and transfer of the Warrant. The
name and address of the holder of the Warrant, the transfers thereof and the name and address of the transferee of the Warrant
shall be registered in such Warrant Register. The Person in whose name the Warrant shall be so registered shall be deemed and treated
as the owner and holder thereof for all purposes of this Warrant, and the Company shall not be affected by any notice or knowledge
to the contrary.

 

(c)          Upon
the surrender of this Warrant, properly endorsed, for registration of transfer or for exchange at the office of the Company maintained
pursuant to Section 10.2(a) hereof, the Company at its expense will (subject to compliance with Section 9 hereof,
if applicable) execute and deliver to or upon the order of the Holder thereof a new Warrant of like tenor, in the name of such
holder or as such holder (upon payment by such holder of any applicable transfer taxes) may direct, calling in the aggregate on
the face thereof for the number of shares of Common Stock called for on the face of the Warrant so surrendered (after giving effect
to any previous adjustment(s) to the number of Warrant Shares).

 

    	 	14	 

     

    

 

10.3       Replacement
of Warrant. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of any such loss, theft or destruction of this Warrant, upon delivery of indemnity reasonably satisfactory
to the Company in form and amount or, in the case of any mutilation, upon surrender of this Warrant for cancellation at the office
of the Company maintained pursuant to Section 10.2(a) hereof, the Company will execute and deliver, in lieu thereof, a new
Warrant of like tenor and dated the date hereof.

 

10.4       Opinions.
In connection with the sale of the Warrant Shares by Holder, the Company agrees to cooperate with the Holder if the Company’s
counsel determines such opinion is appropriate, and at the Company’s expense, to have its counsel provide any legal opinions
required to remove the restrictive legends from the Warrant Shares in connection with a sale, transfer or legend removal request
of Holder.

 

11.         No
Rights or Liabilities as Stockholder. Except as provided in Section 4.4, no Holder shall be entitled to vote or receive
dividends or distributions or be deemed the holder of any equity securities which may at any time be issuable on the exercise hereof,
nor shall anything contained herein be construed to confer upon the Holder, as such, any of the rights of a stockholder of the
Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof,
or to give or withhold consent to any corporate action (whether upon any recapitalization, issuance of stock, reclassification
of stock, change of par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or to receive
dividends or distributions, or to share in the assets of the Company in the event of a liquidation, dissolution or the winding
up of the Company, until the Warrant shall have been exercised and the shares of Common Stock purchasable upon the exercise hereof
shall have become deliverable, as provided herein.

 

    	 	15	 

     

    

 

12.         Notices.
Any notice or other communication in connection with this Warrant shall be given in writing and directed to the parties hereto
as follows: (a) if to the Holder, at the address of the holder in the warrant register maintained pursuant to Section 10
hereof; or (b) if to the Company, to the attention of its Chief Executive Officer at its office maintained pursuant to Section
10.2(a) hereof; provided that the exercise of the Warrant shall also be effected in the manner provided in
Section 3 hereof. Notices shall be deemed properly delivered and received when delivered to the notice party (i) if personally
delivered, upon receipt or refusal to accept delivery, (ii) if sent via facsimile, upon mechanical confirmation of successful transmission
thereof generated by the sending telecopy machine, (iii) if sent by a commercial overnight courier for delivery on the next Business
Day, on the first Business Day after deposit with such courier service, or (iv) if sent by registered or certified mail, five (5)
Business Days after deposit thereof in the U.S. mail.

 

13.         Payment
of Taxes. The Company will pay all documentary stamp taxes attributable to the issuance of shares of Common Stock underlying
this Warrant upon exercise of this Warrant; provided, however, that the Company shall not be required to pay any tax
which may be payable in respect of any transfer involved in the transfer or registration of this Warrant or any certificate for
shares of Common Stock underlying this Warrant in a name other that of the Holder. The Holder is responsible for all other tax
liability that may arise as a result of holding or transferring this Warrant or receiving shares of Common Stock underlying this
Warrant upon exercise hereof.

 

14.         Miscellaneous.
This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the
Company and the Majority Holders. This Warrant shall be construed and enforced in accordance with and governed by the laws of the
State of New York. The section headings in this Warrant are for purposes of convenience only and shall not constitute a part hereof.
When used herein, the term “Reasonable Commercial Efforts” means, with respect to the applicable obligation
of the Company, reasonable commercial efforts for similarly situated, publicly-traded companies.

 

(Signature on Following Page)

 

    	 	16	 

     

    

 

IN WITNESS WHEREOF, the
Company has caused this Underwriter Warrant to be duly executed as of the date first above written.

 

	 	CUE BIOPHARMA, INC.
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

    	 	17	 

     

    

 

EXHIBIT A

FORM OF EXERCISE NOTICE

[To be executed only upon exercise of Warrant]

 

To CUE BIOPHARMA, INC.:

 

The undersigned registered holder of the
within Warrant hereby irrevocably exercises the Warrant pursuant to Section 3.1 of the Warrant with respect to [_____] Warrant
Shares, at an exercise price of $[____] per share, and requests that the certificates for such Warrant Shares be issued,
subject to Sections 9 and 10, in the name of and delivered to:

 

The undersigned is hereby making payment for
the Warrant Shares in the following manner:

[check one]

 

		 ̈	by cash in accordance with Section 3.1(b) of the Warrant

 

		 ̈	via cashless exercise in accordance with Section 3.1(c) of the Warrant in the following manner:

 

The undersigned hereby represents and warrants
that it is, and has been since its acquisition of the Warrant, the record and beneficial owner of the Warrant.

 

	Dated:	 	 

 

	 
	Print or Type Name
	 
	 
	(Signature must conform in all respects to name of holder as specified on the face of Warrant)
	 
	 
	(Street Address)
	 	 	 
	 	 	 
	(City)	(State)	(Zip Code)

 

     

     

    

 

EXHIBIT B

FORM OF ASSIGNMENT

[To be executed only upon transfer of Warrant]

 

For value received, the undersigned registered
holder of the within Warrant hereby sells, assigns and transfers unto_____________________[include name and addresses] the rights
represented by the Warrant to purchase__________ shares of Common Stock of CUE BIOPHARMA, INC. to which the Warrant relates, and
appoints Attorney to make such transfer on the books of CUE BIOPHARMA, INC. maintained for the purpose, with full power of substitution
in the premises.

 

Dated:

	 
	(Signature must conform in all respects to name of holder as specified on the face of Warrant)
	 
	 
	(Street Address)
	 
	 
	(City)	(State)	(Zip Code)

 

Signed in the presence of:

 

	 
	(Signature of Transferee)
	 
	 
	(Street Address)
	 
	 
	(City)	(State)	(Zip Code)

 

Signed in the presence of:Exhibit 10.2

 

Dated as of                     ,
2017

 

MDB Capital Group,
LLC

2425 Cedar Springs Road

Dallas, Texas 75201

 

Ladies and Gentlemen:

 

This
agreement is being delivered to you in connection with the proposed Underwriting Agreement (the “Underwriting Agreement”)
between Cue Biopharma, Inc., a Delaware corporation (the “Company”), and MDB Capital Group, LLC (“MDB”)
relating to a proposed public offering, on a best efforts basis (the “Offering”), of shares (the “Shares”)
of the Company’s Common Stock (the “Common Stock”).

 

In
order to induce MDB to enter into the Underwriting Agreement, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the undersigned agrees that, during the period beginning on and including the date of the Underwriting
Agreement through and including the one year anniversary of the date of the Underwriting Agreement (the “Lock-Up Period”),
the undersigned, or any affiliated party of the undersigned, will not, without the prior written consent of MDB, directly or indirectly:

 

		(i)	offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option
or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of any shares of Common
Stock or any securities convertible into or exercisable or exchangeable for Common Stock, owned or with respect to which the undersigned
has acquired the power of disposition as of the date of the Underwriting Agreement, or

 

		(ii)	enter into any swap or other agreement, arrangement or transaction that transfers to another, in
whole or in part, directly or indirectly, any of the economic consequence of ownership of any Common Stock or any securities convertible
into or exercisable or exchangeable for any Common Stock, owned or with respect to which the undersigned has acquired the power
of disposition as of the date of the Underwriting Agreement,

 

whether any transaction
described in clause (i) or (ii) above is to be settled by delivery of Common Stock, other securities, in cash or otherwise.
Moreover, if:

 

		(1)	during the last 17 days of the Lock-Up Period, the Company issues an earnings release or material
news or a material event relating to the Company occurs, or

 

		(2)	prior to the expiration of the Lock-Up Period, the Company announces that it will release earnings
results during the 16-day period beginning on the last day of the Lock-Up Period,

 

     

     

    

 

the Lock-Up Period
shall be extended and the restrictions imposed by this agreement shall continue to apply until the expiration of the 18-day period
beginning on the date of issuance of the earnings release or the occurrence of the material news or material event, as the case
may be, unless MDB waives, in writing, such extension.

 

Notwithstanding
the provisions set forth in the immediately preceding paragraph, the undersigned may, without the prior written consent of MDB,
(1) transfer any Common Stock or any securities convertible into or exchangeable or exercisable for Common Stock as a bona
fide gift or gifts, or by will or intestacy, to any member of the immediate family (as defined below) of the undersigned or to
a trust the beneficiaries of which are exclusively the undersigned or members of the undersigned’s immediate family or to
a charity or educational institution; provided, however, that it shall be a condition to the transfer that, if
the undersigned is required to file a report under Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), reporting a reduction in beneficial ownership of Common Stock or any securities convertible into or exercisable
or exchangeable for Common Stock by the undersigned during the Lock-Up Period (as the same may be extended as described above),
the undersigned shall include a statement in such report to the effect that such transfer or distribution is not a transfer for
value and that such transfer is being made as a gift or by will or intestacy, as the case may be; (2) exercise or convert
currently outstanding warrants, options and convertible debentures, as applicable, and exercise options under an acceptable stock
option plan, so long as the undersigned agrees that the shares of Common Stock received from any such exercise or conversion will
be subject to this agreement; (3) if the undersigned is a corporation, partnership, limited liability company, trust or other business
entity, (A) transfer any Common Stock or any securities convertible into or exchangeable or exercisable for Common Stock to another
corporation, partnership, limited liability company, trust or other business entity that is a direct or indirect affiliate (as
defined in Rule 405 promulgated under the Securities Act of 1933, as amended (the “1933 Act”)) of the undersigned
or (B) distribute shares of Common Stock or any securities convertible into or exercisable for Common Stock to limited partners,
limited liability company members or stockholders of the undersigned; (4) if the undersigned is a trust, transfer to the beneficiary
of such trust; or (5) transfer any Common Stock or any securities convertible into or exchangeable or exercisable for Common Stock
pursuant to the Underwriting Agreement; provided, in the case of clauses (1) through (4), that (x) such transfer shall not
involve a disposition for value and (y) if applicable, the transferee executes and delivers to MDB not later than one business
day prior to such transfer, a written agreement, in substantially the form of this agreement and otherwise satisfactory in form
and substance to MDB. For purposes of this paragraph, “immediate family” shall mean a spouse, child, grandchild or
other lineal descendant (including by adoption), father, mother, brother or sister of the undersigned.

 

The
undersigned further agrees that (i) it will not, during the Lock-Up Period (as the same may be extended as described above),
make any demand for or exercise any right with respect to the registration under the 1933 Act, of any Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock, including under any current or future registration rights agreement
or similar agreement to which the undersigned is a party or under which the undersigned is entitled to any right or benefit to
have any securities included in a registration statement filed by the Company for resale or other transaction, and (ii) the
Company may, with respect to any Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock
owned or held (of record or beneficially) by the undersigned, cause the transfer agent or other registrar to enter stop transfer
instructions and implement stop transfer procedures with respect to such securities during the Lock-Up Period (as the same may
be extended as described above).

 

     

     

    

 

The
foregoing restrictions shall not apply to (i) any shares of Common Stock the undersigned may purchase in the Offering or in open
market transactions after the completion of the Offering; provided, that no filing under Section 16(a) of the Exchange Act
shall be required by reason of the undersigned’s being an officer or director of the Company or shall be voluntarily made
during the Lock-Up Period in connection with subsequent sales of Common Stock acquired in such transactions or (ii) the establishment
of any contract, instruction or plan that satisfies all the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act (a “Plan”);
provided, that no sales of the undersigned’s securities shall be made pursuant to such a Plan prior to the expiration of
the Lock-Up Period and such a Plan may only be established if no public announcement of the establishment or existence thereof
and no filing with the SEC or other regulatory authority in respect thereof or transactions thereunder or contemplated thereby,
by the undersigned, the Company or any other person, shall be required, and no such announcement or filing is made voluntarily
by the undersigned, the Company or any other person, prior to the expiration of the Lock-Up Period.

 

In
addition, the undersigned hereby waives any and all notice requirements and rights with respect to the registration of any securities
pursuant to any current or future agreement, instrument, understanding or otherwise, including any registration rights agreement
or similar agreement, to which the undersigned is a party or under which the undersigned is entitled to any right or benefit and
any tag-along rights or other similar rights to have any securities (debt or equity) included in the offering contemplated by the
Underwriting Agreement or sold in connection with the sale of Common Stock pursuant to the Underwriting Agreement, provided that
such waiver shall apply only to the public offering of Common Stock pursuant to the Underwriting Agreement and each registration
statement filed under the 1933 Act in connection therewith.

 

The
undersigned understands that, if the Underwriting Agreement does not become effective, or if the Underwriting Agreement (other
than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the
securities to be sold thereunder, the undersigned shall be released from all obligations under this Agreement.

 

The
undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this agreement and that
this agreement has been duly executed and delivered by the undersigned and is a valid and binding agreement of the undersigned.
This agreement and all authority herein conferred are irrevocable and shall survive the death or incapacity of the undersigned
and shall be binding upon the heirs, personal representatives, successors and assigns of the undersigned.

 

[Signature Page
Immediately Follows]

 

     

     

    

 

	 	Yours very truly,
	 	 
	 	 
	 	Print Name:	 

 

Signature Page
— Cue Biopharma Lock-up Letter to MDB Capital Group, LLC

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}]]